TheraVet Announces Positive Safety and Efficacy Results for BIOCERA-VET® in Canine Osteosarcoma

Affiliate Disclosure: Center for Dog Pain Relief, Inc. sometimes uses affiliate links within our content. This comes at no cost to you but helps us to be able to create more helpful content!

GOSSELIES, Wallonia, Belgium–TheraVet’s BIOCERA-VET® was evaluated in a prospective non-controlled multicentric clinical research in client-owned dogs with osteosarcoma. 12 dogs were treated with a percutaneous cimentoplasty as a palliative therapy for the disease. After one month, 67 percent of the dogs reported a reduction in discomfort of at least 50 percent. Quality of life was enhanced in 78% of the animals after one month and 50% after two and six months. The same decrease levels were detected with the CBPI’s pain severity (PSS) and pain interference with function (PIF) ratings, but somewhat less4. For more information, visit the TheraVet.
 

Read the full press release at Business Wire

 

Facebook
Twitter
LinkedIn
Pinterest
Email
Leave a Reply

Your email address will not be published.